An observational study in Cryptogenic Ischemic Stroke, sponsored by Niguarda Hospital. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Niguarda Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Ischemic Stroke with a site in Italy — 23 open to participants now, 29 under way, 2 of them phase 3. Ischemic Stroke · Italy.
Among the 81 studies in Ischemic Stroke with a site in Italy, this one is the 25th largest by planned enrollment of the 30 observational ones that give a count, is one of 11 that started in 2025, is one of 30 observational ones, reaches primary completion later than 21 of the 28 other live ones, and was the 79th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →23 of the 81 studies in Ischemic Stroke with a site in Italy are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Italy, Belgium, Germany and 3 more countries
Ages 18+
Azienda Usl di Bologna · Sites in Italy
Ages 18+
Italian Society of Vascular and Endovascular Surgery · Sites in Italy
Ages 45–90
Corxel Pharmaceuticals · Sites in Italy, United States, Belgium and 18 more countries
Ages 18–90
University of Milano Bicocca · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 10 · Phase 4 5
First in 2000; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is below the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 227 across the 50 interventional studies, 550 across the 30 observational. Of the 40 that completed or were terminated, 13 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 81 have an industry lead sponsor. The 10 most frequent:
Niguarda Hospital is the lead sponsor of 68 studies on the registry; 29 are open to participants now.
Niguarda Hospital has 3 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
7 of the studies in Ischemic Stroke with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06710028Fondazione Policlinico Universitario Agostino Gemelli IRCCSTrustworthy Artificial Intelligence for Improvement of Stroke Outcomes | 2026-11-30 |
| NCT07199322Fondazione Don Carlo Gnocchi ETSClinical validatiOn of an AI-based DEcision Support System for Robotic Upper Limb Rehabilitation in Patients With Stroke. A CO-AIDER Study. | 2026-12 |
| NCT04562194VesalioNeVa ONE Registry Study | 2026-12-31 |
| NCT04339699Nobles Medical Technologies II IncNobleStitch EL STITCH Trial is a PFO Comparative Trial | 2026-12-31 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
Add all 7 to your calendar (.ics) → With an account.
Among the 81 studies in Ischemic Stroke with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The CATCH ME study is a prospective, multicenter, observational, no-profit study aimed at improving embolic risk stratification in patients with embolic stroke of undetermined source (ESUS), particularly in those with left ventricular disease (LVD). LVD is defined by a mildly to moderately reduced ejection fraction (30-49%), left ventricular wall motion abnormalities (hypo/akinesia), ventricular dilation, cardiomyopathies, and other related conditions. In these patients, the intermittent formation of intracardiac thrombi within the ventricle, often undetectable by standard diagnostic evaluation such as transthoracic echocardiography (TTE) alone, may serve as an unrecognized embolic source. However, in clinical practice, such patients are frequently discharged on antiplatelet therapy alone, without adequate thromboembolic risk stratification, thus leaving them at a high risk of ischemic recurrence. This study aims to assess the additional diagnostic value of advanced cardiac imaging - Cardiac Magnetic Resonance Imaging (CMRI) and/or Cardiac Computed Tomography (CCT) - in detecting intracardiac thrombi not identified by TTE in patients with ESUS and LVD.
ESUS is a subgroup of ischemic stroke characterized by several potential embolic sources and represents a significant challenge in clinical management. Among ESUS patients, those with LVD, defined as a mildly to moderately reduced ejection fraction (30-49%), left ventricular wall motion abnormalities (LVWMAs), ventricular dilation, cardiomyopathies, and other related conditions, constitute a high-risk subgroup for adverse outcomes. In this population, the underlying stroke mechanism could be the intermittent formation of intraventricular thrombi. Factors such as low cardiac output, dilated cardiac chambers, poor contractility, and endothelial dysfunction may activate Virchow's triad, thereby increasing the risk of thrombosis. The standard cardiac diagnostic approach for these patients typically includes TTE, which is often unable to detect small intracardiac thrombi, due to their transient nature or the limited sensitivity of TTE. This limitation may lead to a diagnostic gap, with the potential risk of not implementing adequate secondary prevention therapy. In fact, these patients are usually discharged with antiplatelet therapy, despite several studies showing a higher risk of stroke recurrence. Advanced cardiac imaging techniques, including CCT and CMRI, are increasingly being used in the diagnostic evaluation of ESUS patients. Studies have demonstrated their role in identifying significant vascular and cardiac abnormalities not otherwise detected by TTE, leading to a reclassification of the stroke etiology and a consequent reduction in the ESUS prevalence. Current AHA/ASA guidelines recommend the use of advanced cardiac imaging (CMRI and CCT) in selected ESUS cases to optimize preventive therapy and reduce the risk of recurrence (class 2b, level of evidence C). CMRI, in particular, is recommended when (1) there is suspicion of an intracardiac thrombus but TTE results are inconclusive, or (2) TTE is negative but there remains a clinical suspicion of a cardioembolic stroke etiology. Studies have shown that both CCT and CMRI allow for the detection of cardiac thrombi significantly more often than TTE in ESUS patients, especially those with markers of LVD. CMRI is considered the gold standard for non-invasive evaluation of the left ventricle and has the highest sensitivity in detecting ventricular thrombi. Despite the relatively widespread use of advanced cardiac imaging in selected ESUS cases, there is currently a lack of systematic data on its clinical utility in this specific population. This study aims to assess the role of advanced cardiac imaging (CMRI and/or CCT) in detecting intracardiac thrombi in ESUS patients with LVD compared to the use of TTE alone. This study intends to provide real-world evidence on the additional diagnostic value of advanced cardiac imaging, contributing to a better understanding of its utility in secondary stroke prevention.
The study will last for three years, with a recruitment period of two years and 1 year of follow-up. It will be conducted in three phases:
The main goal is to evaluate the diagnostic effectiveness of advanced cardiac imaging (CMRI and/or CCT) in identifying intracardiac thrombi in ESUS patients with LVD who have negative TTE results (no thrombi). The study will also aim to determine the prevalence of intracardiac thrombi detected by TTE in all patients with ESUS and LVD. Additionally, it will assess the clinical and cardiac differences between patients based on whether thrombi are present and the method used for detecting them. The study will examine how the results from CMRI and/or CCT influence therapeutic decisions, such as the initiation of anticoagulant therapy when thrombi are found. Furthermore, the study will evaluate the risk of adverse events during follow-up, including recurrent strokes, coronary events, major bleeding episodes, and mortality.
Patients aged between 18 and 85 years, with an mRS score ≤ 4 and Ischemic stroke classified as ESUS according to standard criteria, with LVD (defined as moderately reduced ejection fraction 30-49%, presence of LC wall motion abnormalities, LV aneurysm, LV dilatation with or without spontaneous echo-contrast, non-compacted LV [with deep trabeculations or spongy LV], cardiomyopathies [severe restrictive cardiomyopathy, cardiac amyloidosis, hypertrophic cardiomyopathy]), in whom no intracardiac thrombi are identified on transthoracic echocardiogram and who are able to undergo advanced cardiac imaging (CMRI and/or CCT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of LVD defined by at least one of the following criteria:
Patients capable of signing (IC) or, in the case of unconscious patients without an authorized legal representative, recruited in a "Deferred" mode
Exclusion Criteria:
Patients under 60 years of age with a high-risk patent foramen ovale (PFO) and stroke classified as "probable" PFO-associated stroke according to the PASCAL classification.
Pregnancy or puerperium. to MRI and CT with contrast agents
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with embolic stroke of undetermined source and left ventricular disease, with no intracardiac thrombus identified on transthoracic echocardiography, will undergo advanced cardiac imaging such as cardiac MRI and/or CT
Prevalence of left ventricular thrombus on advanced cardiac imaging (CMRI and/or CCT)
Prevalence of left ventricular thrombus detected by advanced cardiac imaging (CMR, CCT) compared with transthoracic echocardiography (TTE) in patients who underwent both investigations within 15 days of the index stroke
Time frame: 15 days from the index stroke
Intracardiac thrombi detected by transthoracic echocardiography in all patients with ESUS and LVD. Recurrent ischemic stroke Systemic embolism Acute coronary events Major bleeding, defined by the International Society of Thrombosis and Hemostasis Mortal
Incidence of major cardiovascular events (MACE) at 12 months
Time frame: 12 months from the index stroke
Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.
Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 36 months is below that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Niguarda Hospital